J&J's prostate cancer drug Zytiga approved in EU
Men with advanced cases of prostate cancer who have already undergone chemotherapy have been allowed access to a new, secondary treatment drug for the disease.
Zytiga, manufactured by pharmaceutical company Johnson & Johnson, has just been approved for use in Europe and in April it was given the go-ahead in America by the US Food and Drug Administration (FDA).
The new drug was approved by the European Commission after an accelerated review by the European Medicines Agency.
In both the US and Europe, Zytiga has been approved for use when taken in conjunction with the prednisone steroid.
To read the latest edition of Healthcare Global, click here
- UK’s ban on gay blood donations could soon be removed
- iPads test for early signs of dementia and Alzheimer’s
- Ovaries should be removed in women with cancer risk
The drug works by preventing the production of the testosterone hormone in the testes and the tumour itself, therefore limiting, if not stooping, the tumour from growing.
In a statement released by Johnson & Johnson, the company commented: “A trial of nearly 1,200 patients showed that those treated with Zytiga and prednisone lived an average of four months longer than those treated with prednisone and a options.”
It is thought the drug is likely to be well received by patients as other treatments of a similar nature are only available in injection form, whereas Zytiga is a once-a-day oral pill.
Our magazine is now available on the iPad. Click here to download it.
Dubai's new smart neuro spinal hospital: need to know
We take a look at Dubai's new smart hospital.
What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah. It is also the UAE’s first hospital to have surgical robots.
Where: The hospital is located in the Dubai Science Park. Founded in 2005, Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day.
Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital.
Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.
Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.
"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”